AN2 Therapeutics, Inc. (ANTX) Misses Q1 EPS by 10c

AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q1 EPS of ($0.35), $0.10 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• TD Cowen on Boston Scientific (BSX): 'Shipping Confirmed With Physician Contacts', 'We view the news as a big step forward'
• BlackRock’s Rosenberg says inflation data key after jobs beat